Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Announces Data on SUL-DUR to be Presented at IDWeek 2022

Stock Information for Entasis Therapeutics Holdings Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Entasis Therapeutics Holdings Inc.

Innoviva Announces Expiration of Cash Tender Offer for Shares of Entasis Therapeutics Holdings Inc.
SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates TMX, HR, MN, MICT, ETTX
The M&A Class Action Firm Continues to Investigate Entasis Therapeutics Holdings Inc. - ETTX
SHAREHOLDER ALERT: Weiss Law Reminds BHVN, SWCH, ETTX, and TVTY Shareholders About Its Ongoing Investigations
INVESTIGATION ALERT: Halper Sadeh LLP Investigates FHLT, TVTY, MN, ETTX
SHAREHOLDER ALERT: Weiss Law Reminds ETTX, TVTY, MANT, and RTLR Shareholders About Its Ongoing Investigations
Entasis Therapeutics Presents Data on Sulbactam-Durlobactam and ETX0462 at 2022 ASM Microbe Annual Conference
INVESTIGATION ALERT: Halper Sadeh LLP Investigates MANT, ETTX, CTEK

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.